このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Cellectar Biosciences 将来の成長

Future 基準チェック /56

Cellectar Biosciencesは、65.4%と56.6%でそれぞれ年率65.4%で利益と収益が成長すると予測される一方、EPSはgrowで69.9%年率。

主要情報

67.7%

収益成長率

70.5%

EPS成長率

Biotechs 収益成長	35.4%
収益成長率	57.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	13 Sep 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:NV4 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	113	15	N/A	N/A	3
12/31/2025	51	-25	N/A	N/A	3
12/31/2024	N/A	-63	N/A	N/A	3
3/31/2024	N/A	-51	-39	-39	N/A
12/31/2023	N/A	-38	-33	-32	N/A
9/30/2023	N/A	-38	-31	-30	N/A
6/30/2023	N/A	-32	-29	-29	N/A
3/31/2023	N/A	-31	-28	-27	N/A
12/31/2022	N/A	-29	-25	-25	N/A
9/30/2022	N/A	-27	-23	-22	N/A
6/30/2022	N/A	-25	-22	-22	N/A
3/31/2022	N/A	-24	-23	-23	N/A
12/31/2021	N/A	-24	-23	-23	N/A
9/30/2021	N/A	-22	-22	-22	N/A
6/30/2021	N/A	-20	-19	-19	N/A
3/31/2021	N/A	-17	-15	-15	N/A
12/31/2020	N/A	-15	-14	-14	N/A
9/30/2020	N/A	-15	-13	-13	N/A
6/30/2020	N/A	-15	-13	-13	N/A
3/31/2020	N/A	-14	-12	-12	N/A
12/31/2019	N/A	-14	-12	-12	N/A
9/30/2019	N/A	-15	-12	-12	N/A
6/30/2019	N/A	-16	-12	-11	N/A
3/31/2019	N/A	-16	-11	-11	N/A
12/31/2018	N/A	-15	-12	-11	N/A
9/30/2018	N/A	-17	-12	-12	N/A
6/30/2018	N/A	-15	-11	-11	N/A
3/31/2018	N/A	-16	-11	-11	N/A
12/31/2017	N/A	-15	N/A	-11	N/A
9/30/2017	N/A	-15	N/A	-11	N/A
6/30/2017	N/A	-14	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-9	N/A	-8	N/A
9/30/2016	N/A	-3	N/A	-7	N/A
6/30/2016	N/A	-2	N/A	-7	N/A
3/31/2016	N/A	-2	N/A	-8	N/A
12/31/2015	N/A	-5	N/A	-8	N/A
9/30/2015	N/A	-10	N/A	-9	N/A
6/30/2015	N/A	-8	N/A	-9	N/A
3/31/2015	N/A	-7	N/A	-9	N/A
12/31/2014	N/A	-8	N/A	-9	N/A
9/30/2014	N/A	-9	N/A	-9	N/A
6/30/2014	N/A	-10	N/A	-10	N/A
3/31/2014	N/A	-10	N/A	-10	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NV4は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 0.8% ) よりも高い成長率であると考えられます。

収益対市場: NV4今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: NV4今後 3 年以内に収益を上げることが予想されます。

収益対市場: NV4の収益 ( 56.6% ) German市場 ( 5.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: NV4の収益 ( 56.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NV4の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Cellectar Biosciences 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Recent updates

Cellectar Biosciences Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Cellectar Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Cellectar Biosciences, Inc. Announces Positive Results Data from its Ongoing CLover WaM Pivotal Study Evaluating Iopofosine I 131 for the Treatment of Relapsed/Refractory Waldenstrom's Macroglobulinemia

New major risk - Share price stability

Insufficient new directors

Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

New minor risk - Market cap size

New major risk - Financial position

No longer forecast to breakeven

Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

New major risk - Shareholder dilution

Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study

Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Forecast to breakeven in 2026

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Forecast to breakeven in 2026

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.

New major risk - Financial position

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

New major risk - Share price stability

Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc. Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

Cellectar Biosciences, Inc. Announces Resolution of Breach of Contract and Intellectual Property Dispute

Cellectar Biosciences, Inc. announced that it has received $3.911327 million in funding

Cellectar Biosciences, Inc. Wins $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Cellectar Biosciences, Inc. Announces Publication of Data from its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

Nasdaq Grants Extension to Cellectar Biosciences Until October 31, 2022 to Regain Compliance

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

Cellectar Biosciences, Inc. Presents Data from Its Ongoing Phase 2 Clover-1 Study of Iopofosine I-131 At the 63rd Ash Annual Meeting and Exposition

Cellectar Biosciences, Inc. Announces the Completion of the Part A Portion of A Safety and Tolerability Study of Iopofosine I-131 (Iopofosine) in Combination with External Beam Radiation (Ebrt) in Relapsed or Refractory Head and Neck Cancer

High number of new directors

Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster At the 2021 American Society of Clinical Oncology Annual Meeting

Cellectar Biosciences, Inc. Receives Notification of Formal Grant of the Patent Titled Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles by the Eurasian, Australian and Mexican Patent Authorities

Cellectar Biosciences, Inc. Announces Japan Patent Office Granted Patent, Titled, 'Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles'

New 90-day low: €1.40

Cellectar Biosciences, Inc. Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

Cellectar Biosciences, Inc. announced that it has received $20.5065 million in funding

Cellectar Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $24.499984 million.

Cellectar Biosciences, Inc. announced that it expects to receive $20.5 million in funding

New 90-day high: €2.10

New 90-day high: €1.51

Cellectar Biosciences, Inc. Announces CLR 131 Has Demonstrated Preliminary Activity in Inoperable Brain Tumors in Phase 1 Study

New 90-day low - €0.94

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘